Households in Great Britain that include a user of weight-loss drugs such as Mounjaro or Wegovy are saving more than £400 a year on grocery bills, according to new research. The study by Worldpanel by Numerator found that the number of adults taking GLP-1 medications has nearly tripled in two years, reaching 1.9 million.
The research, based on a survey of more than 11,600 households, revealed that 6.3% of British households now contain at least one GLP-1 user, up from 4.1% in 2025 and 2.3% in 2024. In the year after starting the drugs, these households spent £780 million less on groceries than expected compared with similar households, buying 299 million fewer items in February alone.
More than half of users described their eating as “mindful”, with reduced cravings and less “food noise”. Three-quarters cut back on chocolate and 72% on crisps, with chocolate confectionery spend falling 18 percentage points more in user households. Two-fifths of users want smaller restaurant portions, and over a quarter requested a GLP-1-friendly menu section when eating out.
A common side-effect, dry mouth and bad breath known as “Ozempic mouth”, led to increased purchases of mouthwash and chewing gum, up 20 and 24 percentage points respectively in user households. However, cost remains a barrier, with 41% of users stopping medication in 2026 due to price.
Chantel Kennaugh, head of public sector and nutrition GB for Worldpanel by Numerator, said: “What was once a specialised treatment, primarily prescribed for type 2 diabetes, has in just a few short years become a mainstream force. Now, 68% of users are taking GLP-1s specifically to lose weight.”
Retailers are adapting: Marks & Spencer launched a “nutrient-dense” food range in January, and Ocado created a virtual “weight management” aisle to cater to the growing number of consumers on weight-loss jabs.
